The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy
- 1 August 2017
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1868 (1) , 221-230
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Trends in incidence and survival for anal cancer in New South Wales, Australia, 1972–2009Cancer Epidemiology, 2015
- Anal Cancer Incidence in the United States, 1977–2011: Distinct Patterns by Histology and BehaviorCancer Epidemiology, Biomarkers & Prevention, 2015
- Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trialThe Lancet Oncology, 2013
- Changing Patterns of Anal Canal Carcinoma in the United StatesJournal of Clinical Oncology, 2013
- Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage LevelsJNCI: Journal of the National Cancer Institute, 2013
- Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/CisplatinJournal of Clinical Oncology, 2012
- Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North AmericaClinical Infectious Diseases, 2012
- Immunosuppressive disorders and risk of anal squamous cell carcinoma: A nationwide cohort study in Denmark, 1978–2005International Journal of Cancer, 2010
- Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysisInternational Journal of Cancer, 2009
- Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canalCancer, 1983